Abbott U.S. Pharma Head Is Goffredo: Higgins Becomes Enzon CEO
Abbott's U.S. pharmaceutical business will be headed by former VP-European Operations David Goffredo following the departure of Senior VP-Pharmaceutical Operations Arthur Higgins to become CEO of Enzon.
You may also be interested in...
Abbott sees potential marketing synergies between the triglyceride-lowering agent TriCor (fenofibrate) and Knoll's obesity agent Meridia (sibutramine).
Abbott is casting aside its traditional formula for senior drug management and turning its pharmaceutical division over to the recently recruited head of research, Jeffrey Leiden, MD/PhD.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011